Home / Articles Posted by Team MT (Page 21)
Team MT 346POSTS

jd@medgatetoday.com

388e1b1c c91b 4de5 a1b6 4fb4559c6b8c e1762841457203

In a significant medical advancement, researchers at a Gurugram-based institute have reported a major breakthrough in the treatment of children suffering from Sickle Cell

7
1cabcb52 ffaa 47e0 a956 69aec99940c9 1 e1762838674357

Investment to expand manufacturing and global medicine supply capacity — resonating with the Make in India agenda   Eli Lilly and Company today announced plans to

8
thumbnail Image 01 e1762777140573

The Vascular Surgeons Association of Karnataka (VASKAR) organized the Walkathon 2025 today in Bengaluru under the inspiring theme “Amputation-Free India.” Over 500 doctors, vascular specialists, and paramedical professionals came together

DIA AAVH MOU for press 2 scaled e1762773905282

Dementia India Alliance (DIA), a national, NGO dedicated to promoting awareness, advocacy, and care for people living with dementia, and Apollo AyurVAID Hospitals, India’s

8
PHOTO 2 1 e1762773050579

This world-class eye care facility has been built at an investment of around Rs 75 crore. With this expansion, Sankara Eye Hospital, Pedakakani,

6
unnamed e1762756445506

Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6% Syngene International Limited today announced financial results for the second quarter and half year of FY26.   Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins)     Q2 FY25 Q2 FY26 YoY Change (%) Revenue from Operations 891 911 2% Reported Revenue 908 926 2% Reported EBITDA 261 215 -18% Reported EBITDA margin (%) 28.8% 23.2%   Reported PAT (before exceptional items) 106 67 -37% Reported PAT Margin (%) 11.7% 7.3%   H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins)     H1 FY25 H1 FY26 YoY Change (%) Revenue from Operations 1,681 1,785 6% Reported Revenue 1,715 1,818 6% Reported EBITDA 449 439 -2% Reported EBITDA margin (%) 26.2% 24.1%   Reported PAT (before exceptional items) 161* 154 -4% Reported PAT Margin (%) 9.4% 8.5%   Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim.   Commenting on

7
55d4e2e4 6ad2 4c6a a940 5c6112ba49eb

The approvals strengthen India’s position as a reliable supplier of advanced pharmaceuticals across ASEAN markets where Venus Remedies already exports more than 374 products.   Venus

Dr.Mathai scaled e1762754237383

Commits ₹125 crore investment to develop its first 100-bed integrative AYUSH hospital in Bengaluru   SOUKYA International Holistic Health Centre, globally acclaimed for its premium holistic

7
cda4bd74 9f30 4845 ac99 4903da6cefb5 e1762238946980

The Delhi High Court has dismissed a plea challenging the Food Safety and Standards Authority of India (FSSAI)’s directive banning the sale of beverages

c90debbd ef8b 4e94 984a b902222ccb9b e1762238404420

India’s leading vaccine innovator Bharat Biotech has announced the establishment of a Contract Research, Development, and Manufacturing Organization (CRDMO) division dedicated to cell and